Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than contro

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announ

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi

Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market sessi

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the anal

Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rate

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~

The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposur

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseH

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy an

This milestone triggers the final phase of preparation for the trial's interim 45 subject data u

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the ana

Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announc

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials– Thi

    Tuesday's session saw 729 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Thursday